Author:
Kalden Joachim R.,Schulze-Koops Hendrik
Publisher
Springer Science and Business Media LLC
Reference117 articles.
1. Rothe, A., Power, B. E. & Hudson, P. J. Therapeutic advances in rheumatology with the use of recombinant proteins. Nat. Clin. Pract. Rheumatol. 4, 605–614 (2008).
2. Cantarovich, D. et al. Treatment of acute kidney rejection episodes with monoclonal antibody directed against IL2 receptor: a pilot study. Transplant. Proc. 21, 1785–1786 (1989).
3. Cantarovich, D. et al. Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin. Transplant. Proc. 21, 1769–1771 (1989).
4. Horneff, G., Burmester, G. R., Emmrich, F. & Kalden, J. R. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 34, 129–140 (1991).
5. Elliott, M. J. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105–1110 (1994).
Cited by
133 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献